www.magazine-industry-usa.com
25
'24
Written on Modified on
Bayer News
VIVIDION THERAPEUTICS TO EXPAND WITH NEW GLOBAL RESEARCH AND DEVELOPMENT CENTER
New facility in San Diego will support continued development of Vividion’s global discovery and clinical portfolio.
Courtesy of Alexandria Real Estate Equities, Inc.
Vividion Therapeutics, a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. Vividion is a wholly owned and independently operating subsidiary of Bayer AG.
The new facility will support the continued development of Vividion’s R&D capabilities, including a significant increase in the company’s chemoproteomics screening capacity. More than half of the expansion will be dedicated to state-of-the-art research labs where Vividion will continue advancing its expansive portfolio of clinical and preclinical programs as well as future programs that emerge from the company’s discovery efforts. The new facility will accommodate strategic growth capabilities and enable the company to continue to attract and retain top life sciences experts in San Diego, a rapidly growing hub for biotech innovation.
Bayer has a long-standing track record of delivering scientific innovation for patients. Rebuilding the portfolio, enhancing R&D capabilities, and an ongoing reallocation of resources – including commitment to building on its strong presence in the United States – are key parts of the company’s strategy to achieve sustainable long-term growth. San Diego’s world-renowned biotech cluster is home to hundreds of life science companies and leading research institutes that have made significant contributions to advancements in healthcare. Such an ecosystem holds great promise for Bayer to strengthen its leadership and innovation pipeline. In addition to San Diego, Bayer has successfully developed a local presence in each of the United States’ most innovative life science hubs, including Boston, San Francisco and Research Triangle Park - North Carolina.
Vividion Therapeutics, a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. Vividion is a wholly owned and independently operating subsidiary of Bayer AG.
The new facility will support the continued development of Vividion’s R&D capabilities, including a significant increase in the company’s chemoproteomics screening capacity. More than half of the expansion will be dedicated to state-of-the-art research labs where Vividion will continue advancing its expansive portfolio of clinical and preclinical programs as well as future programs that emerge from the company’s discovery efforts. The new facility will accommodate strategic growth capabilities and enable the company to continue to attract and retain top life sciences experts in San Diego, a rapidly growing hub for biotech innovation.
Bayer has a long-standing track record of delivering scientific innovation for patients. Rebuilding the portfolio, enhancing R&D capabilities, and an ongoing reallocation of resources – including commitment to building on its strong presence in the United States – are key parts of the company’s strategy to achieve sustainable long-term growth. San Diego’s world-renowned biotech cluster is home to hundreds of life science companies and leading research institutes that have made significant contributions to advancements in healthcare. Such an ecosystem holds great promise for Bayer to strengthen its leadership and innovation pipeline. In addition to San Diego, Bayer has successfully developed a local presence in each of the United States’ most innovative life science hubs, including Boston, San Francisco and Research Triangle Park - North Carolina.
www.bayer.com
